Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q495A1
UPID:
TIGIT_HUMAN
Alternative names:
V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain-containing protein 3
Alternative UPACC:
Q495A1; Q495A3; Q5JPD8; Q6MZS2; Q8N877
Background:
The T-cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as V-set and immunoglobulin domain-containing protein 9 or V-set and transmembrane domain-containing protein 3, plays a pivotal role in immune regulation. It binds with high affinity to the poliovirus receptor (PVR), influencing the immune response through modulation of cytokine secretion. This interaction leads to an increased secretion of IL10 and a decreased secretion of IL12B, pivotal in the suppression of T-cell activation and the promotion of mature immunoregulatory dendritic cells.
Therapeutic significance:
Understanding the role of T-cell immunoreceptor with Ig and ITIM domains could open doors to potential therapeutic strategies. Its ability to modulate immune responses positions it as a key target in the development of treatments for autoimmune diseases and in the enhancement of cancer immunotherapy efficacy.